Lv35
232 积分 2023-07-26 加入
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus
2天前
已完结
Bioinformatically Informed Design of Synthetic Mammalian Promoters
15天前
已完结
63881 Oral IL-17A Small Molecule Inhibitors Designed by Generative AI with Biologics-Like Potency for Psoriasis Treatment
17天前
已完结
Target identification and assessment in the era of AI
18天前
已完结
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
28天前
已完结
Varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain (CART19-BE-02): a multicentre, single-arm, phase 2 trial
1个月前
已完结
Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study
1个月前
已完结
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
1个月前
已完结
Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma
1个月前
已完结
Preclinical development and a case report of a nanobody-based CLDN18.2 CAR-T IMC002 with reduced on-target off-tumor toxicity
1个月前
已完结
皖公网安备34019202002308
